Hipertensión pulmonar crónica tromboembólica
Chronic Thromboembolic Pulmonary Hypertension
Peter Fedullo, Kim M. Kerr, Nick H. Kim, and William R. Auger1
Division of Pulmonary and Critical Care Medicine, University of California, San Diego, San Diego, California
Am J Respir Crit Care Med Vol 183. pp 1605-1613, 2011
http://www.atsjournals.org/doi/pdf/10.1164/rccm.201011-1854CI
Hipertensión pulmonar crónica tromboembólica. Manejo médico
Chronic thromboembolic pulmonary hypertension: Medical treatment.
Ozsu S, Cinarka H.
Pulm Circ. 2013 Apr;3(2):341-344.
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is responsible for significant levels of morbidity and mortality. The estimated cumulative incidence of CTEPH is 2-4% among patients presenting with acute pulmonary thromboembolism. Currently, at the time of CTEPH diagnosis, 37.9% of the patients in an international registry were receiving at least one pulmonary arterial hypertension (PAH)-targeted therapy. Advanced medical therapy is considered in patients with inoperable disease, as a bridge to pulmonary endarterectomy or in those with persistent or recurrent pulmonary hypertension. PAH-specific medical therapies include endothelin receptor antagonists, phosphodiesterase inhibitors, and prostacyclin analogues. The present article will focus on recent developments in the pharmacological treatment of CTEPH.
KEYWORDS: chronic thromboembolism, medical treatment, pulmonary hypertension
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757827/
Atentamente
Anestesiología y Medicina del Dolor
www.anestesia-dolor.org
Chronic Thromboembolic Pulmonary Hypertension
Peter Fedullo, Kim M. Kerr, Nick H. Kim, and William R. Auger1
Division of Pulmonary and Critical Care Medicine, University of California, San Diego, San Diego, California
Am J Respir Crit Care Med Vol 183. pp 1605-1613, 2011
http://www.atsjournals.org/doi/pdf/10.1164/rccm.201011-1854CI
Hipertensión pulmonar crónica tromboembólica. Manejo médico
Chronic thromboembolic pulmonary hypertension: Medical treatment.
Ozsu S, Cinarka H.
Pulm Circ. 2013 Apr;3(2):341-344.
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is responsible for significant levels of morbidity and mortality. The estimated cumulative incidence of CTEPH is 2-4% among patients presenting with acute pulmonary thromboembolism. Currently, at the time of CTEPH diagnosis, 37.9% of the patients in an international registry were receiving at least one pulmonary arterial hypertension (PAH)-targeted therapy. Advanced medical therapy is considered in patients with inoperable disease, as a bridge to pulmonary endarterectomy or in those with persistent or recurrent pulmonary hypertension. PAH-specific medical therapies include endothelin receptor antagonists, phosphodiesterase inhibitors, and prostacyclin analogues. The present article will focus on recent developments in the pharmacological treatment of CTEPH.
KEYWORDS: chronic thromboembolism, medical treatment, pulmonary hypertension
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757827/
Atentamente
Anestesiología y Medicina del Dolor
www.anestesia-dolor.org
No hay comentarios:
Publicar un comentario